{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:55:59Z","timestamp":1790805359769,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01293","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T05:15:58Z","timestamp":1592975758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin"],"prefix":"10.3389","volume":"11","author":[{"given":"Moanaro","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Palaschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep R. P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Markusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2450\/2019.0253-18","article-title":"Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years","volume":"17","author":"Zanon","year":"2019","journal-title":"Blood Transfus."},{"key":"B3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1160\/TH14-07-0621","article-title":"Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. a patient-level meta-analysis","volume":"113","author":"Marcucci","year":"2015","journal-title":"Thromb Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2741\/4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front Biosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/emmm.201302857","article-title":"Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice","volume":"5","author":"Annoni","year":"2013","journal-title":"EMBO Mol Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"14013","DOI":"10.1038\/mtm.2014.13","article-title":"Development of gene transfer for induction of antigen-specific tolerance","volume":"1","author":"Sack","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1160\/TH14-01-0078","article-title":"Rituximab for treatment of inhibitors in haemophilia A. A phase II study","volume":"112","author":"Leissinger","year":"2014","journal-title":"Thromb Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1160\/TH16-05-0404","article-title":"Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin","volume":"117","author":"Biswas","year":"2017","journal-title":"Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e37671","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2018.05.001","article-title":"Helper-free production of laboratory grade AAV and purification by iodixanol density gradient centrifugation","volume":"10","author":"Crosson","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"14030","DOI":"10.1038\/mtm.2014.30","article-title":"Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia","volume":"1","author":"Sarkar","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","article-title":"High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors","volume":"106","author":"Hausl","year":"2005","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/hae.12522","article-title":"Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4","volume":"21","author":"Sack","year":"2015","journal-title":"Haemophilia."},{"key":"B32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2516.2010.02397.x","article-title":"Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb\/c and C57BL\/6 haemophilia A mice","volume":"17","author":"Qadura","year":"2011","journal-title":"Haemophilia."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","article-title":"Induction of tolerance to factor VIII by transient co-administration with rapamycin","volume":"9","author":"Moghimi","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/blood-2014-09-599266","article-title":"Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg","volume":"125","author":"Biswas","year":"2015","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/mt.2009.301","article-title":"BALB\/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver","volume":"18","author":"Breous","year":"2010","journal-title":"Mol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nri3802","article-title":"Memory B cells","volume":"15","author":"Kurosaki","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2003-07-2456","article-title":"Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders","volume":"104","author":"Hausl","year":"2004","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/mtm.2015.56","article-title":"Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A","volume":"3","author":"Lytle","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/bloodadvances.2018027979","article-title":"FVIII expression driven by its native promoter by lentiviral vectors allowed sustained long-term FVIII expression blunting immune responses in hemophilic Mice","volume":"26","author":"Fama","year":"2018","journal-title":"Mol Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.ymthe.2017.04.029","article-title":"A novel platform for immune tolerance induction in hemophilia A Mice","volume":"25","author":"Merlin","year":"2017","journal-title":"Mol Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/mt.2008.292","article-title":"Enhanced factor VIII heavy chain for gene therapy of hemophilia A","volume":"17","author":"Chen","year":"2009","journal-title":"Mol Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1182\/blood-2012-02-412361","article-title":"A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function","volume":"120","author":"Meeks","year":"2012","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"16083","DOI":"10.1038\/mtm.2016.83","article-title":"Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer","volume":"3","author":"Perrin","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The balance between CD8(+) T cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J Pediatr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"14033","DOI":"10.1038\/mtm.2014.33","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1111\/hae.13583","article-title":"rFIXFc for immune tolerance induction in a severe hemophilia b patient with an inhibitor and prior history of ITI related nephrotic syndrome","volume":"24","author":"Malec","year":"2018","journal-title":"Haemophilia."},{"key":"B53","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/jth.14740","article-title":"Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors","volume":"18","author":"Doshi","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B54","doi-asserted-by":"publisher","first-page":"E5076","DOI":"10.1073\/pnas.1407104111","article-title":"mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition","volume":"111","author":"Limon","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.immuni.2017.06.005","article-title":"Germinal center selection and affinity maturation require dynamic regulation of mTORC1 kinase","volume":"46","author":"Ersching","year":"2017","journal-title":"Immunity."},{"key":"B56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/gt.2016.34","article-title":"Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment","volume":"23","author":"Wang","year":"2016","journal-title":"Gene Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2016.01.005","article-title":"Strategies to target long-lived plasma cells for treating hemophilia A inhibitors","volume":"301","author":"Liu","year":"2016","journal-title":"Cell Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T05:16:02Z","timestamp":1592975762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2020.01293"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01293","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"article-number":"1293"}}